Exploring expression levels of the cGAS-STING pathway genes in peripheral blood mononuclear cells of spinal tuberculosis patients.

Ingentiumby Ingentium

In Tuberculosis Literature.

Exploring expression levels of the cGAS-STING pathway genes in peripheral blood mononuclear cells of spinal tuberculosis patients.

Publication date: Sep 04, 2024

This study aimed to investigate the differential expression levels of the cGAS-STING pathway in peripheral blood mononuclear cells (PBMCs) of spinal tuberculosis (TB) patients with different progression and its feasibility as a diagnostic marker. Peripheral blood and medical records of 25 patients with spinal TB and 10 healthy individuals, were prospectively collected and analyzed. PBMCs and serum were extracted from peripheral blood and the expression levels of the cGAS-STING pathway in PBMCs were measured by real-time PCR (RT-PCR) and serum interferon β (IFN-β) expression levels were measured by enzyme-linked immunosorbent assay (ELISA). The expression of Interferon regulatory Factor 3 (IRF3) in PBMCs was measured using western blot. Statistical analysis was performed using the SPSS 26. 0 statistical package. The results showed that the expression level of the TANK-binding kinase 1 (TBK1) and IRF3 was significantly higher in PBMCs (P 

Open Access PDF

Concepts Keywords
Higher Activity
Pcr cGAS-STING
Serum Diagnostic marker
Tbk1 PBMCs
Tuberculosis Spinal tuberculosis

Semantics

Type Source Name
disease IDO blood
disease MESH spinal tuberculosis
disease IDO assay
pathway REACTOME Reproduction
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease MESH death
disease MESH kyphosis
disease MESH paraplegia
disease MESH deformity
disease MESH recurrent infections
disease IDO intervention
disease MESH postoperative complications
disease IDO host
pathway REACTOME Immune System
pathway REACTOME Autophagy
drug DRUGBANK Trestolone
disease IDO production
drug DRUGBANK Methyl isocyanate
disease MESH pus
disease MESH infections
disease MESH Brucellosis
disease MESH spondylitis
disease MESH bacterial infections
disease MESH viral infections
disease IDO immunodeficiency
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH ankylosing spondylitis
disease MESH systemic lupus erythematosus
pathway KEGG Systemic lupus erythematosus
disease MESH tumors
disease MESH renal insufficiency
drug DRUGBANK Methionine
disease MESH lumbago
disease MESH back pain
drug DRUGBANK Isopropyl Alcohol
drug DRUGBANK Water
drug DRUGBANK Cysteamine
drug DRUGBANK Sodium lauryl sulfate
disease MESH abscesses
disease MESH chronic wasting disease
disease MESH anemia
drug DRUGBANK Urea
drug DRUGBANK Nitrogen
drug DRUGBANK Creatinine
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Saquinavir
disease MESH morbidity
disease MESH scoliosis
disease MESH latent infection
disease IDO infection
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin
disease IDO replication
disease MESH Streptococcus pneumoniae infection
disease MESH inflammation
pathway REACTOME Apoptosis
disease MESH granulomas
disease MESH COVID 19
disease MESH latent tuberculosis
drug DRUGBANK Troleandomycin
disease MESH Extrapulmonary tuberculosis
disease IDO cell
drug DRUGBANK Linezolid
disease IDO drug susceptibility
disease MESH complications

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *